- Home
- NSTS vs CRBP Comparison
NSTS vs CRBP Comparison
Compare NSTS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- CRBP
- Stock Information
- Founded
- NSTS 1921
- CRBP 2009
- Country
- NSTS United States
- CRBP United States
- Employees
- NSTS N/A
- CRBP N/A
- Industry
- NSTS Savings Institutions
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- CRBP Health Care
- Exchange
- NSTS Nasdaq
- CRBP Nasdaq
- Market Cap
- NSTS 65.8M
- CRBP 73.4M
- IPO Year
- NSTS N/A
- CRBP N/A
- Fundamental
- Price
- NSTS $11.78
- CRBP $6.45
- Analyst Decision
- NSTS
- CRBP Strong Buy
- Analyst Count
- NSTS 0
- CRBP 10
- Target Price
- NSTS N/A
- CRBP $53.56
- AVG Volume (30 Days)
- NSTS 1.6K
- CRBP 147.8K
- Earning Date
- NSTS 05-20-2025
- CRBP 05-06-2025
- Dividend Yield
- NSTS N/A
- CRBP N/A
- EPS Growth
- NSTS N/A
- CRBP N/A
- EPS
- NSTS N/A
- CRBP N/A
- Revenue
- NSTS $8,931,000.00
- CRBP N/A
- Revenue This Year
- NSTS N/A
- CRBP N/A
- Revenue Next Year
- NSTS N/A
- CRBP $150.00
- P/E Ratio
- NSTS N/A
- CRBP N/A
- Revenue Growth
- NSTS 82.49
- CRBP N/A
- 52 Week Low
- NSTS $9.37
- CRBP $4.64
- 52 Week High
- NSTS $13.32
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- NSTS 53.97
- CRBP 46.87
- Support Level
- NSTS $11.72
- CRBP $6.10
- Resistance Level
- NSTS $11.70
- CRBP $8.07
- Average True Range (ATR)
- NSTS 0.09
- CRBP 0.71
- MACD
- NSTS 0.04
- CRBP -0.10
- Stochastic Oscillator
- NSTS 100.00
- CRBP 13.31
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in our market area of Lake County, Illinois and adjacent communities.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.